In multiple sclerosis (MS), certain disease-driving immune cells carry a protein marker called CD29, which helps them move into the brain and trigger inflammation. That is the key finding of a new study by researchers in the Netherlands, who zeroed in on the protein as a driver of MS.
Discussion
The European Medicines Agency (EMA) has granted PRIME designation to Oculis‘ experimental treatment privosegtor for optic neuritis, a condition commonly seen in people with multiple sclerosis (MS). Optic neuritis, marked by inflammation of the optic nerve that carries signals between the eyes and the brain, can…
Discussion
A new model of nerve fibers may serve as a platform to screen for experimental treatments that can promote myelin repair in multiple sclerosis (MS), a study showed. The model is made of soft micropillars around which myelin-producing cells can wrap myelin. Researchers found that some drugs tended to…
Discussion
Quantum Biopharma has officially filed with the U.S. Food and Drug Administration (FDA) for clearance to begin a Phase 2 clinical trial of Lucid-MS, a “first-in-class” oral therapy designed to halt the progression of multiple sclerosis (MS) by protecting myelin, or the protective sheath around nerves in…
Discussion
MS Canada is inviting cyclists across the country to take part in its 2026 MS Bike season, a series of fundraising rides aimed at supporting Canadians living with multiple sclerosis (MS). The annual MS Bike series brings together thousands of participants to ride scenic routes while raising money…
Get regular updates to your inbox.
